Co-transduction-aware digital twinning of dual-AAV prime editing for genetically stratified CNS therapy

Abstract Dual-AAV prime editing could deliver precise gene correction to the central nervous system, but its therapeutic yield depends on a chain of events co-delivery of both vectors to the same cell, editor reconstitution, editing, and rescue that is usually measured separately in different systems. This study presents DUAL-AAV PRIME-DT, an evidence-constrained digital twin that treats AAV-A/AAV-B co-transduction as an explicit cell-level state and propagates it through the whole therapeutic chain. In a synthetic cohort of 10,000 virtual patients with LRRK2-associated Parkinson disease, mean therapeutic coverage is 1.24% (patient-level 5th\95th percentile, 0.12–3.93%), with joint delivery and editing causing the largest losses. Perfect co-transduction raises mean coverage by 74%, whereas assuming independent vectors changes it by only − 5%. Stress tests, sensitivity analysis, and value-of-information analysis identify delivery, reconstitution, and editing as principal levers and show that a terminal phenotype cannot reveal which step failed. All outputs are synthetic and imply no clinical efficacy; the framework specifies the matched same-cell measurements required to replace synthetic priors and to test its predictions.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-17
DOI
https://doi.org/10.21203/rs.3.rs-11747124/v1
Primary Topic
Virus-based gene therapy research
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Co-transduction-aware digital twinning of dual-AAV prime editing for genetically stratified CNS therapy

Faizan Ahmad
2 links
Research Square
Virus-based gene therapy research
preprint

Co-transduction-aware digital twinning of dual-AAV prime editing for genetically stratified CNS therapy

Faizan Ahmad
preprint en

Abstract

Abstract Dual-AAV prime editing could deliver precise gene correction to the central nervous system, but its therapeutic yield depends on a chain of events co-delivery of both vectors to the same cell, editor reconstitution, editing, and rescue that is usually measured separately in different systems. This study presents DUAL-AAV PRIME-DT, an evidence-constrained digital twin that treats AAV-A/AAV-B co-transduction as an explicit cell-level state and propagates it through the whole therapeutic chain. In a synthetic cohort of 10,000 virtual patients with LRRK2-associated Parkinson disease, mean therapeutic coverage is 1.24% (patient-level 5th\95th percentile, 0.12–3.93%), with joint delivery and editing causing the largest losses. Perfect co-transduction raises mean coverage by 74%, whereas assuming independent vectors changes it by only − 5%. Stress tests, sensitivity analysis, and value-of-information analysis identify delivery, reconstitution, and editing as principal levers and show that a terminal phenotype cannot reveal which step failed. All outputs are synthetic and imply no clinical efficacy; the framework specifies the matched same-cell measurements required to replace synthetic priors and to test its predictions.

Research Square
Jamia Hamdard (IN)
Good health and well-being
Virus-based gene therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon